Trevogrumab dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Regeneron's antibody that blocks myostatin, used alone or with garetosmab, which blocks activin A. Added to semaglutide, it saved 51 to 81 percent of the muscle people would have lost. The three-drug group had more side effects.
Evidence grade for Trevogrumab: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Muscle and strength
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Trevogrumab is an antibody from Regeneron that blocks myostatin, a brake on muscle. It is being tested with semaglutide, alone or with garetosmab, which blocks activin A. The goal is to keep muscle during weight loss. It is not approved.
What people take it for
- Keeping muscle on semaglutide.
- Losing more fat on semaglutide.
What studies in people showed
In a mid-stage study, adding trevogrumab to semaglutide saved about 51 percent of the muscle people normally lose. Adding both antibodies saved 80.9 percent. People on all three drugs lost 27.3 percent more fat than on semaglutide alone. But the three-drug group had more side effects. Two people in the study died. The deaths were not blamed on the drugs. These are company figures.
What people report
Reports, not study results
The good
- In the studies on this page, people on all three drugs kept about 81 percent of the muscle normally lost.
The bad
- The three-drug group had more side effects in the study on this page.
- Two people in the study died. The researchers did not blame the drugs.
Where these come from: All of it is from the Regeneron releases on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Great muscle numbers, with a safety question hanging over them. Not ready. Lift.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Trevogrumab has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing fat specificallyno headcount stated · 1 study
- Keeping or building muscleno headcount stated · 1 study
34 of the 36 indexed goals have no study of any kind behind Trevogrumab
No study in people, animals or cells on this page reports a result for these. That does not prove Trevogrumab does nothing for them. It does mean anything you have heard about Trevogrumab and one of these did not come from a study cited here.
Show full evidence
What is Trevogrumab?
Regeneron's antibody that blocks myostatin, used alone or with garetosmab, which blocks activin A. Added to semaglutide, it saved 51 to 81 percent of the muscle people would have lost. The three-drug group had more side effects.
The mid-stage COURAGE study tested semaglutide alone, semaglutide with trevogrumab, which blocks myostatin, and semaglutide with both trevogrumab and garetosmab, which blocks activin A. Results were shared at a 2025 diabetes meeting. Adding trevogrumab saved about 51 percent of the lean mass normally lost. Adding both saved 80.9 percent and took off 27.3 percent more fat than semaglutide alone. The three-drug group also had more side effects. Two people died, and the deaths were not blamed on the drugs. Full data were expected in 2026. Separately, garetosmab has good final-stage results in fibrodysplasia ossificans progressiva, a rare bone disease.
How does Trevogrumab work?
Trevogrumab blocks myostatin. Garetosmab blocks activin A. Both signals hold back muscle growth, and activin A also helps the body store fat.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- 144,036 Da (trevogrumab; garetosmab is a separate antibody)
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Antibody dosing per trial protocol
No amino acid sequence is on file for Trevogrumab, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025Results from Phase 2 COURAGE trial with semaglutide, trevogrumab and garetosmab
Blocking two muscle brakes at once protected most of the muscle people lose on semaglutide. With all three drugs, about 81% of the muscle normally lost was kept, and people lost about 27% more fat than on semaglutide alone. Two drugs instead of three kept about half. These are company-reported figures from a mid-stage trial. The three-drug group also had more side effects, which is covered in the entry beside this one.
Triple regimen preserved 80.9% of lean mass with 27.3% more fat loss.
- Study in people2025Interim COURAGE results
The strongest combination was also the hardest on people. The group taking all three drugs had more side effects than the others, and two people in the trial died, which the investigators did not attribute to the drugs. That is the cost side of the muscle-sparing result reported alongside it. These are interim company figures from a mid-stage trial, and the full data set was still to come.
Higher adverse-event rate in the triple arm.
Common questions
Has Trevogrumab been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Regeneron's antibody that blocks myostatin, used alone or with garetosmab, which blocks activin A. Added to semaglutide, it saved 51 to 81 percent of the muscle people would have lost. The three-drug group had more side effects.
What is the Trevogrumab dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Trevogrumab FDA-approved?
Investigational (obesity)
Is muscle preservation worth the added risk?
That is exactly what COURAGE cannot yet answer. The muscle numbers are strong for a drug added to a GLP-1. But the safety results mean the combination is far from ready for use.